Introduction: The majority of available therapeutics to treat attention-deficit/hyperactivity
disorder (ADHD) are formulations of either methylphenidate or amphetamine. However …

Abstract Objective: Edivoxetine (LY2216684) is a selective and potent norepinephrine
reuptake inhibitor (NERI). The pharmacokinetics (PK) and pharmacodynamics (PD) of …

Objective: The purpose of this study was to assess the efficacy and safety of edivoxetine
(LY2216684), a selective norepinephrine reuptake inhibitor, in pediatric patients with …

Purpose To assess the impact of hepatic or renal impairment on the pharmacokinetics (PK)
of edivoxetine. Methods Two separate multi-center, open-label studies with males and …

Objective: The purpose of this study was to assess the clinical outcomes from an open label
study of edivoxetine, a selective norepinephrine reuptake inhibitor, in pediatric patients with …

Objective: The purpose of this study was to assess the long-term safety and tolerability of
edivoxetine, a selective norepinephrine reuptake inhibitor, which was being developed as …

Attention-deficit hyperactivity disorder (ADHD) is associated with substantial functional,
clinical and economic burdens. It is among the most common psychiatric disorders in …

Methylphenidate, amphetamines, and atomoxetine are established agents used to treat
children, adolescents, and adults with attention-deficit/hyperactivity disorder (ADHD) …

This study evaluated the efficacy and safety of lisdexamfetamine dimesylate (LDX)
compared with placebo in children and adolescents with attention-deficit/hyperactivity …

Lisdexamfetamine (LDX) has been a recent addition to the treatment armamentarium for
Attention Deficit Hyperactivity Disorder (ADHD). It is unique among stimulants as it is a …